The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
R | Respiratory system | |
2
|
R03 | Drugs for obstructive airway diseases | |
3
|
R03D | Other systemic drugs for obstructive airway diseases | |
4
|
R03DX | Other systemic drugs for obstructive airway diseases | |
5
|
R03DX10 |
| Active Ingredient |
|---|
|
Benralizumab is an anti-eosinophil, humanised afucosylated, monoclonal antibody (IgG1, kappa). It specifically binds to the alpha subunit of the human interleukin-5 receptor (IL-5Rα). The IL-5 receptor is specifically expressed on the surface of eosinophils and basophils. The absence of fucose in the Fc domain of benralizumab results in high affinity for FcɣRIII receptors on immune effector cells such as natural killer (NK) cells. This leads to apoptosis of eosinophils and basophils through enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), which reduces eosinophilic inflammation. |
| Document | Type | Information Source | |
|---|---|---|---|
| FASENRA Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) | |
| FASENRA Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.